rs587780155
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 9P and 0B. PVS1PP5
The NM_005732.4(RAD50):c.326_329del(p.Thr109AsnfsTer20) variant causes a frameshift change. The variant allele was found at a frequency of 0.000018 in 1,611,166 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. K108K) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_005732.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
RAD50 | NM_005732.4 | c.326_329del | p.Thr109AsnfsTer20 | frameshift_variant | 3/25 | ENST00000378823.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
RAD50 | ENST00000378823.8 | c.326_329del | p.Thr109AsnfsTer20 | frameshift_variant | 3/25 | 1 | NM_005732.4 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.0000197 AC: 3AN: 152238Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000318 AC: 8AN: 251216Hom.: 0 AF XY: 0.0000295 AC XY: 4AN XY: 135770
GnomAD4 exome AF: 0.0000178 AC: 26AN: 1458928Hom.: 0 AF XY: 0.0000248 AC XY: 18AN XY: 726022
GnomAD4 genome ? AF: 0.0000197 AC: 3AN: 152238Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74382
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneKor MSA | Jan 09, 2021 | This variation is a deletion of 4 nucleotides from exon 3 of the RAD50 mRNA, causing a frameshift after codon 109 and the creation of a premature translation stop signal 20 amino acid residues later - p.(Thr109Asnfs*20). This is expected to result in an absent or disrupted protein product. The mutation database ClinVar contains entries for this variant (Variation ID: 128017). - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Dec 10, 2023 | This sequence change creates a premature translational stop signal (p.Thr109Asnfs*20) in the RAD50 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RAD50 are known to be pathogenic (PMID: 19409520). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 26023681). ClinVar contains an entry for this variant (Variation ID: 128017). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 07, 2021 | The c.326_329delCAGA pathogenic mutation, located in coding exon 3 of the RAD50 gene, results from a deletion of 4 nucleotides at nucleotide positions 326 to 329, causing a translational frameshift with a predicted alternate stop codon (p.T109Nfs*20). In one study, this mutation was reported in 6/60,466 breast cancer cases and in 1/53,461 controls (Dorling et al. N Engl J Med. 2021 02;384:428-439).This mutation has also been reported in multiple individuals with personal and/or family histories of breast, colon, prostate, and other cancers (Foley SB et al. EBioMedicine. 2015 Jan;2:74-81; Schrader KA et al. JAMA Oncol. 2016 Jan;2:104-11; Kotoula V et al. Am J Cancer Res, 2017 Jan;7:98-114; Coppa A et al. Cancer Med. 2018 Jan;7:46-55; Perkins BA et al. Proc. Natl. Acad. Sci. U.S.A. 2018 Apr;115:3686-3691; Carlo MI et al. J Clin Oncol, 2020 02;38:406-414; Akcay IM et al. Int J Cancer, 2021 01;148:285-295). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Breast carcinoma Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Medical Genetics Laboratory, Umraniye Training and Research Hospital, University of Health Sciences | Aug 09, 2021 | - - |
Nijmegen breakage syndrome-like disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | May 22, 2022 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Oct 01, 2022 | RAD50: PVS1:Moderate, PM2:Supporting - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at